Clinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number
|
|
- Curtis Campbell
- 6 years ago
- Views:
Transcription
1 EudrCT Number A Phse I, Rndomised, Open-lbel, 3-wy Cross-over Study in Helthy Volunteers to Demonstrte the Bioequivlence of the Nloxegol 25 mg Commercil nd Phse III Formultions nd to Assess the Effect of Food Administrtion on the Phrmcokinetics of the Commercil Formultion Study dtes: First subject enrolled: 03 July 2012 Lst subject lst visit: 11 September 2012 Phse of development: Clinicl phrmcology (I) This study ws performed in complince with Good Clinicl Prctice, including the rchiving of essentil documents.
2 Publictions None t the time of writing this clinicl study report (CSR). Objectives nd criteri for evlution Tble S1 Objectives nd outcome vribles Objective Outcome Vrible Priority Type Description Description Primry Phrmcokinetic (PK) To demonstrte the bioequivlence between two different film-coted tblet formultions of nloxegol, commercil tblet (test) nd Phse III tblet (reference), fter single-dose dministrtion of 25 mg tblet to helthy volunteers under fsted conditions Secondry PK To ssess the effect of food on the PK of nloxegol commercil film-coted tblets Sfety To investigte sfety nd tolerbility of single orl doses of 25 mg nloxegol dministered s two different tblet formultions in helthy volunteers Explortory Phrmcogenetic To collect nd store DNA for future explortory reserch into genes/genetic vrition tht my influence response (ie, distribution, sfety, tolerbility, nd efficcy) C mx, AUC, t mx, t 1/2 λz, λ z, AUC (0-t), AUC (0-24), CL/F, nd V z /F C mx, AUC, t mx, t 1/2 λz, λ z, AUC (0-t), AUC (0-24), CL/F, nd V z /F Adverse events (AEs), lbortory ssessments, results of physicl exmintion, electrocrdiogrm (ECG), vitl signs (pulse rte nd blood pressure [BP]), nd C-SSRS Not pplicble Sfety To collect plsm smples for sfety biomrker testing tht will llow future ssessment of sfety biomrkers Not pplicble λ z : terminl rte constnt ; AUC: Are under the plsm concentrtion-time curve from zero extrpolted to infinity; AUC (0-t) : Are under the plsm concentrtion-time curve from zero to the time of the lst quntifible concentrtion; AUC (0-24) : Are under the concentrtion-versus-time curve from time 0 to 24 hours postdose; C mx : Mximum observed plsm concentrtion, obtined directly from the observed concentrtion versus time dt; CL/F: Apprent orl clernce from plsm; DNA: Deoxyribonucleic cid; ECG: Electrocrdiogrm; t mx : Time to mximum plsm concentrtion obtined directly from the observed concentrtion versus time dt; t 1/2 λz : Terminl hlf-life; V z /F: Apprent volume of distribution during the terminl phse Results from the explortory nlyses, if performed, would be reported seprtely from the Clinicl Study Report (CSR). 2
3 Study design This ws single-centre, open-lbel, rndomised, 3-wy cross-over Phse I study in helthy volunteers to demonstrte the bioequivlence of the nloxegol 25 mg film-coted commercil nd Phse III formultions nd to ssess the effect of food on the phrmcokinetics (PK) of the nloxegol commercil formultion. The study comprised of the following visits: Visit 1 (screening; 30 dys of the first dministrtion of the investigtionl product [IP] on Dy 1), Visits 2, 3 nd 4 (tretment period; three rndomised single-dose tretment periods with durtion of 3 dys, ech seprted by wshout period of t lest 7 dys clculted from the time of first dministrtion of nloxegol dose to the next dose dministrtion), nd Visit 5 (follow-up; 7 to 10 dys fter the lst dministrtion of IP). Eligible helthy volunteers were rndomly ssigned to one of the 3 tretments in crossover design in one of the 6 tretment sequences (ABC, BCA, CAB, CBA, ACB, nd BAC)on Dy 1 of Period 1: Tretment A (single orl dministrtion of nloxegol film-coted immedite relese [IR] tblet 25 mg commercil formultion under fsted conditions), Tretment B (single orl dministrtion of nloxogel film-coted IR tblet 25 mg commercil formultion under fed conditions), nd Tretment C (single orl dministrtion of nloxegol film-coted IR tblet 25 mg Phse III formultion under fsted conditions), respectively. Trget subject popultion nd smple size Helthy mle nd femle (non-pregnnt, non-lctting) volunteers ged 18 to 55 yers (inclusive) with body mss index (BMI) between 18 nd 30 kg/m 2 (inclusive) were rndomised in this study. Plnned: Enrolled nd rndomised: Completed: 42 helthy volunteers 42 helthy volunteers 41 helthy volunteers Investigtionl product nd comprtor: dosge, mode of dministrtion nd btch numbers Tble S2 Detils of the investigtionl product Investigtionl product Dosge form nd strength (mode of dministrtion) Mnufcturer Btch number Nloxegol Commercil formultion 25 mg film-coted IR tblet (orl) AstrZenec P Lot: AZ F Lot: AZ Nloxegol IR: Immedite relese Phse III formultion 25 mg film-coted IR tblet (orl) Phrmceutics Interntionl Incorported (PII) P Lot: WK F Lot:
4 Durtion of tretment Single IP dministrtion during ech visit (for 3 tretment periods), ech seprted by wshout period of t lest 7 dys (clculted from the time of the first dministrtion of nloxegol dose to the next dose dministrtion). Sttisticl methods A smple size of 34 evluble helthy volunteers provided t lest 90% power to demonstrte tht nloxegol commercil formultion is bioequivlent to the nloxegol Phse III formultion. Assuming dropout rte less thn 19%, 42 helthy volunteers were enrolled. Study conduct, sfety, nd PK dt were summrised using descriptive sttistics, s pproprite. To mke n ssessment of the primry objective of the study, Tretment A (nloxegol commercil formultion under fsted conditions, test) nd Tretment C (nloxegol Phse III formultion under fsted conditions, reference) were compred sttisticlly. Reltive biovilbility in the fsted stte ws estimted using n nlysis of vrince model with the logrithm of AUC nd C mx (primry) s well s AUC (0-t) nd AUC (0-24) (secondry) for nloxegol s the response vrible; tretment, period, nd sequence s fixed effects; nd volunteer within sequence included s rndom effect. If the 90% CI for the geometric LS mens rtios for both AUC nd C mx fell entirely between the prespecified intervl (80.00% to %), then bioequivlence between the nloxegol commercil formultion nd the Phse III formultion under fsted conditions ws concluded. To mke n ssessment of the effect of food on the nloxegol commercil formultion, the PK prmeters (AUC nd C mx [primry] s well s AUC (0-t) nd AUC (0-24) [secondry]) from the fed rm, Tretment B (test), were compred to tht of the fsted rm, Tretment A (reference). The comprisons were mde using nlysis of vrince model utilising similr methodology s described in the preceding prgrph. Continuous vribles (hemtology, clinicl chemistry, nd vitl signs) were summrised using descriptive sttistics (n, men, stndrd devition [SD], minimum, medin, nd mximum) by tretment group. Ctegoricl vribles were summrised in frequency tbles (frequency nd proportion) by tretment group. Tbultions nd listings of dt for vitl signs nd clinicl lbortory tests re presented. Listings re presented for electrocrdiogrm (ECG) dt nd physicl exmintion results. Results from the Columbi-Suicide Severity Rting Scle (C-SSRS) were presented seprtely in listing only. Subject popultion All 42 helthy volunteers enrolled, were rndomised in the study. All 42 subjects received Tretments A nd B nd 41 subjects received Tretment C. One subject (E ), who received Tretments A nd B, ws withdrwn from the study due to positive cotinine test result on dmission to the study centre on Dy -1 nd did not receive Tretment C. The demogrphic nd bseline chrcteristics of ll subjects were in ccordnce with the inclusion/exclusion criteri of the Clinicl Study Protocol (CSP). 4
5 Summry of phrmcokinetic results Under fsted conditions, nloxegol bsorption ws rpid with pek concentrtions in plsm being chieved within 1 hour post-dose (medin vlue). The men nloxegol plsm concentrtion-time profiles following dministrtion of nloxogel film-coted IR tblet 25 mg commercil formultion (Tretment A) nd nloxegol film-coted IR tblet 25 mg Phse III formultion (Tretment C) in the fsted stte seemed similr. Nloxegol PK prmeters were similr in men vlue between the commercil nd Phse III formultions (Tretments A nd C). Following C mx the decline in nloxegol men plsm concentrtion ws rpid with geometric men t 1/2 λz of 6.99 hours nd 6.55 hours for Tretments A nd C, respectively. The results of the sttisticl comprisons of PK prmeters for tretments A nd C re presented in Tble S3. Tble S3 Sttisticl comprison of primry phrmcokinetic prmeters for tretments A nd C (fsted stte) Prmeter (Units) Tmt Stte n Geo LS men Comprisons 95% CI (%) Pir Rtio (%) 90% CI (%) AUC A Fsted (126.56, ) A/C (89.13, ) (ng h/ml) C Fsted (134.05, ) AUC (0-t) A Fsted (124.48, ) A/C (88.67, 99.60) (ng h/ml) C Fsted (132.42, ) AUC (0-24) A Fsted (123.16, ) A/C (88.38, 99.25) (ng h/ml) C Fsted (131.46, ) C mx A Fsted (33.13, 44.39) A/C (82.42, ) (ng/ml) C Fsted (35.82, 48.10) CI: confidence intervl; Geo: geometric; IR immedite relese; LS lest squres; Tmt: tretment Results bsed on liner mixed effect nlysis of vrince model with terms for sequence, period, nd tretment s fixed effects, nd volunteer within sequence s rndom effect Tretment A: Single orl dministrtion of nloxegol film-coted IR tblet 25 mg commercil formultion (fsted Tretment C: Single orl dministrtion of nloxegol film-coted IR tblet 25 mg Phse III formultion (fsted Under fed conditions (Tretment B), the t mx for the commercil formultion ws prolonged to 2 hours (medin vlue) while men nloxegol plsm concentrtion-time profiles showed higher exposure compred to nloxegol film-coted IR tblet 25 mg commercil formultion dministered in the fsted stte (Tretment A). Nloxegol AUC nd C mx were higher, indicting greter exposure in the presence of food for the commercil formultion. The geometric men t 1/2 λz ws 7.72 hours. The results of sttisticl comprison of primry PK prmeters of the nloxogel commercil formultion in the fed stte (Tretment B) compred to the fsted stte (Tretment A) re shown in Tble S4. 5
6 Tble S4 Sttisticl comprison of primry phrmcokinetic prmeters for Tretments A nd B (fed versus fsted stte) Prmeters Tmt Stte n Geo LS men Comprisons 95% CI (%) Pir Rtio (%) 90% CI (%) AUC A Fsted (126.56, ) B/A (137.09, ) (ng h/ml) B Fed (183.62, ) AUC (0-t) A Fsted (124.48, ) B/A (137.56, ) (ng h/ml) B Fed (181.39, ) AUC (0-24) A Fsted (123.16, ) B/A (135.58, ) (ng h/ml) B Fed (176.86, ) C mx A Fsted (33.13, 44.39) B/A (115.66, ) (ng/ml) B Fed (42.90, 57.49) CI: Confidence intervls; Geo: Geometric; IR: Immedite relese; LS: Lest squres; n: Number of observtions; Tmt: Tretment Results bsed on liner mixed effect nlysis of vrince model with terms for sequence, period, nd tretment s fixed effects, nd volunteer within sequence s rndom effect. Tretment A: Single orl dministrtion of nloxegol film-coted IR tblet 25 mg commercil formultion (fsted Tretment B: Single orl dministrtion of nloxegol film-coted IR tblet 25 mg commercil formultion (fed Summry of sfety results There were no deths, serious dverse events (SAEs) or AEs leding to discontinution (DAEs) reported during the study. All the AEs were considered to be mild in severity nd resolved before the end of the study. The number of helthy volunteers with t lest 1 AE ws similr cross ll tretment groups. No cliniclly relevnt chnges were reported in ny lbortory mesurements, vitl signs, ECGs, or physicl exmintion findings. Overll, the IP under study ws considered well tolerted in the popultion studied. 6
CheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer
CheckMte 53: Rndomized Results of Continuous vs -Yer Fixed-Durtion Nivolumb in Ptients With Advnced Non-Smll Cell Lung Cncer Abstrct 297O Spigel DR, McCleod M, Hussein MA, Wterhouse DM, Einhorn L, Horn
More informationSYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT
Finl Arevited Clinicl Study Report Nme of Sponsor/Compny: Bristol-Myers Squi Ipilimum Individul Study Tle Referring to the Dossier (For Ntionl Authority Use Only) Nme of Finished Product: Yervoy Nme of
More informationAntiviral Therapy 2015; 20: (doi: /IMP2920)
Antivirl Therpy 2015; 20:397 405 (doi: 10.3851/IMP2920) Originl rticle Sfety, tolerbility nd phrmcokinetics of dorvirine, novel HIV non-nucleoside reverse trnscriptse inhibitor, fter single nd multiple
More informationSponsor / Company: Sanofi Drug substance(s): AVE0005 (aflibercept)
These results re supplied for informtionl purposes only. Prescribing decisions should be mde bsed on the pproved pckge insert in the country of prescription. Sponsor / Compny: Snofi Drug substnce(s): AVE0005
More informationSafety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA
Sfety nd Tolerbility of Subcutneous Srilumb nd Intrvenous Tocilizumb in Ptients With RA Pul Emery, 1 Jun Rondon, 2 Anju Grg, 3 Hubert vn Hoogstrten, 3 Neil M.H. Grhm, 4 Ming Liu, 4 Nncy Liu, 3 Jnie Prrino,
More informationThe RUTHERFORD-2 trial in heterozygous FH: Results and implications
The RUTHERFORD-2 tril in heterozygous FH: Results nd implictions Slide deck kindly supplied s n eductionl resource by Professor Derick Rl MD PhD Crbohydrte & Lipid Metbolism Reserch Unit University of
More informationResults. Table 1: Demographic and Baseline Characteristics, Open-Label Safety Population Prior Double-Blind OC/APAP ER (n=77)
Open-Lbel Extension of Rndomized, Double-Blind, Plcebo-Controlled, Phse 3 Study of the Sfety nd Anlgesic Efficcy of MNK-795 Oxycodone/Acetminophen Extended-Relese (OC/APAP ER) Tblets in n Acute Pin Model
More informationEfficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis
Efficcy of Pembrolizumb in Ptients With Advnced Melnom With Stble Brin Metstses t Bseline: A Pooled Retrospective Anlysis Abstrct 1248PD Hmid O, Ribs A, Dud A, Butler MO, Crlino MS, Hwu WJ, Long GV, Ancell
More informationCommunity. Profile Big Horn County. Public Health and Safety Division
Community Helth Profile 2015 Big Horn County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Powell County. Public Health and Safety Division
Community Helth Profile 2015 Powell County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationCommunity. Profile Yellowstone County. Public Health and Safety Division
Community Helth Profile 2015 Yellowstone County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Lewis & Clark County. Public Health and Safety Division
Community Helth Profile 2015 Lewis & Clrk County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Missoula County. Public Health and Safety Division
Community Helth Profile 2015 Missoul County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationCommunity. Profile Anaconda- Deer Lodge County. Public Health and Safety Division
Community Helth Profile 2015 Ancond- Deer Lodge County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12
More informationCommunity. Profile Carter County. Public Health and Safety Division
Community Helth Profile 2015 Crter County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationPresented at the 75 th Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 3-7, 2017 METHODS INTRODUCTION OBJECTIVE
Seven-Yer Interim Results from the ESPRIT 10-Yer Postmrketing Surveillnce Registry of Adlimumb for Moderte to Severe Psorisis Frncisco Kerdel, 1 Aln Menter, 2 Jshin J. Wu, 3 Mreike Bereswill, 4 Dilek Arikn,
More informationOnset of Action and Efficacy of Ibuprofen Liquigel as Compared to Solid Tablets: A Systematic Review and Meta-Analysis
Onset of Action nd Efficcy of Ibuprofen Liquigel s Compred to Solid Tblets: A Systemtic Review nd Met-Anlysis Hnn Al Lwti nd Fkhreddin Jmli Fculty of Phrmcy & Phrmceuticl Sciences, University of Albert,
More informationIntroduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Abstrct 553 André T,
More informationfunction. As a result of a recent increase in the dose being used in clinical investigations, this study was undertaken to evaluate
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jn. 1992, p. 115-12 66-484/92/1115-6$2./ Copyright C 1992, Americn Society for Microbiology Vol. 36, No. 1 Phrmcokinetics of Teicoplnin upon Multiple-Dose Intrvenous
More informationAddendum to the Evidence Review Group Report on Aripiprazole for the treatment of schizophrenia in adolescents (aged years)
Addendum to the Evidence Review Group Report on Aripiprzole for the tretment of schizophreni in dolescents (ged 15-17 yers) Produced by Authors Correspondence to Southmpton Helth Technology Assessments
More informationOriginal Article. Diabetes Metab J 2011;35:26-33 doi: /dmj pissn eissn
Originl Article Dibetes Metb J 211;35:26-33 doi: 1.493/dmj.211.35.1.26 pissn 2233-679 eissn 2233-687 D I A B E T E S & M E T A B O L I S M J O U R N A L Comprison of the Efficcy of Glimepiride, Metformin,
More informationSingle-Molecule Studies of Unlabelled Full-Length p53 Protein Binding to DNA
Single-Molecule Studies of Unlbelled Full-Length p53 Protein Binding to DNA Philipp Nuttll, 1 Kidn Lee, 2 Pietro Ciccrell, 3 Mrco Crminti, 3 Giorgio Ferrri, 3 Ki- Bum Kim, 2 Tim Albrecht 1* 1 Imperil College
More informationPharmacokinetic Characterization of the Novel Pulmonary Delivery Excipient Fumaryl Diketopiperazine
Journl of Dibetes Science nd Technology Volume 4, Issue 5, September 2010 Dibetes Technology Society ORIGINAL ARTICLES Phrmcokinetic Chrcteriztion of the Novel Pulmonry Delivery Excipient Fumryl Diketopiperzine
More informationEfficacy of Sonidegib in Patients With Metastatic BCC (mbcc)
AAD 216 eposter 3368 Efficcy of Sonidegib in Ptients With Metsttic BCC (mbcc) Colin Morton, 1 Michel Migden, 2 Tingting Yi, 3 Mnish Mone, 3 Dlil Sellmi, 3 Reinhrd Dummer 4 1 Stirling Community Hospitl,
More informationA Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation
ORIGINAL CONTRIBUTIONS 3 see relted editoril on pge x A Rndomized Phse III Clinicl Tril of Plecntide, Urogunylin Anlog, in Ptients With Chronic Idiopthic Constiption Philip B. Miner Jr, MD, Willim D. Koltun,
More informationStart ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4
F O R H E A L T H C A R E P R O F E S S I O N A L S For ptients ge 2 yers nd older who re homozygous for the F508del muttion 1,2 Modify the course. Strt tody. Sydney Age 4 F508del/F508del INDICATIONS AND
More informationSTATISTICAL DATA ANALYSIS IN EXCEL
Microrry Center STATISTICAL DATA ANALYSIS IN EXCEL Prt 1 Introduction to Sttistics Dr. Petr Nzrov 14-06-2010 petr.nzrov@crp-snte.lu Sttisticl dt nlysis in Excel COURSE OVERVIEW Objectives The course: Reminds
More informationA review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital
MEDICAL ONCOLOGY A review of the ptterns of docetxel use for hormone-resistnt prostte cncer t the Princess Mrgret Hospitl S.N. Chin MD,* L. Wng MSc, M. Moore MD,* nd S.S. Sridhr MD MSc* ABSTRACT Bckground
More informationAntiviral Therapy 2015; 20: (doi: /IMP2874)
Antivirl Therpy 25; 2:79 79 (doi:.385/imp2874) Originl rticle Single dose permivir for the tretment of cute sesonl influenz: integrted nlysis of efficcy nd sfety from two plcebo-controlled trils Richrd
More informationChilblains (pernio, perniosis) are cold-induced, painful or itching
Nifedipine vs Plcebo for Tretment of Chronic Chilblins: A Rndomized Controlled Tril Ibo H. Souwer, MD 1 Jcobus H. J. Bor, BSc (Mth) 2 Pul Smits, MD, PhD 3 Antoine L. M. Lgro-Jnssen, MD, PhD 1 1 Deprtment
More informationEmerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data
Emerging Options for Thromboprophylxis After Orthopedic Surgery: A Review of Clinicl Dt Bob L. Lobo, Phrm.D. In four rndomized, controlled studies of ptients undergoing orthopedic surgery, the ntithrombotic
More informationFeeding state and age dependent changes in melaninconcentrating hormone expression in the hypothalamus of broiler chickens
Supplementry Mterils Epub: No 2017_23 Vol. 65, 2018 https://doi.org/10.183/bp.2017_23 Regulr pper Feeding stte nd ge dependent chnges in melninconcentrting hormone expression in the hypothlmus of broiler
More informationUsing Paclobutrazol to Suppress Inflorescence Height of Potted Phalaenopsis Orchids
Using Pcloutrzol to Suppress Inflorescence Height of Potted Phlenopsis Orchids A REPORT SUBMITTED TO FINE AMERICAS Linsey Newton nd Erik Runkle Deprtment of Horticulture Spring 28 Using Pcloutrzol to Suppress
More informationIMpower133: Primary PFS, OS, and safety in a Ph1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC
IMpower133: Primry PFS, OS, nd sfety in Ph1/3 study of 1L tezolizumb + crbopltin + etoposide in extensive-stge SCLC S. V. Liu, 1 A. S. Mnsfield, 2 A. Szczesn, 3 L. Hvel, 4 M. Krzkowski, 5 M. J. Hochmir,
More informationPharmacokinetics of Single-Dose Oral Ciprofloxacin in Patients Undergoing Chronic Ambulatory Peritoneal Dialysis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 1986, p. 152-156 0066-4804/86/070152-05$02.00/0 Copyright 1986, Americn Society for Microbiology Vol. 30, No. 1 Phrmcokinetics of Single-Dose Orl Ciprofloxcin
More informationDebra A. Ignaut, R.N., B.S., C.D.E., and Haoda Fu, Ph.D.
Journl of Dietes Science nd Technology Volume 6, Issue 2, Mrch 2012 Dietes Technology Society TECHNOLOGY REPORT Comprison of Insulin Diluent Lekge Postinjection Using Two Different Needle Lengths nd Injection
More informationThe Acute Time Course of Concurrent Activation Potentiation
Mrquette University e-publictions@mrquette Exercise Science Fculty Reserch nd Publictions Exercise Science, Deprtment of 1-1-2010 The Acute Time Course of Concurrent Activtion Potentition Luke Grceu Mrquette
More informationOpioid Use and Survival at the End of Life: A Survey of a Hospice Population
532 Journl of Pin nd Symptom Mngement Vol. 32 No. 6 December 2006 NHPCO Originl Article Opioid Use nd Survivl t the End of Life: A Survey of Hospice Popultion Russell K. Portenoy, MD, Un Sibircev, BA,
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Pge The hndle http://hdl.hndle.net/1887/5818 holds vrious files of this Leiden University disserttion Author: Olofsen, E. Title: Phrmcokinetic nd phrmcodynmic nlysis in nesthesi : modeling odyssey
More informationY. Yazici 1, D. Moniz Reed 2, C. Klem 2, L. Rosenblatt 2, G. Wu 2, J.M. Kremer 3
Greter remission rtes in ptients with erly versus long-stnding disese in biologic-nive rheumtoid rthritis ptients treted with btcept: post hoc nlysis of rndomised clinicl tril dt Y. Yzici 1, D. Moniz Reed
More informationThe accuracy of creatinine clearance with and without
Postgrd Med J (1991) 67, 42-46 ) The Fellowship of Postgrdute Medicine, 1991 The ccurcy of cretinine clernce with nd without urine collection s mesure of glomerulr filtrtion rte D.G. Wller,' J.S. Fleming,2
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. doi: /ajg.2012.
A 12-Week, Rndomized, Controlled Tril with 4-Week Rndomized Withdrwl Period to Evlute the Efficcy nd Sfety of Linclotide in Irritble Bowel Syndrome with Constiption The Hrvrd community hs mde this rticle
More informationSingle-Dose Accumulation Pharmacokinetics of Tobramycin and Netilmicin in Normal Volunteers
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1987, p. 65-69 66-484/87/465-5$2./ Copyright 1987, Americn Society for Microbiology Vol. 31, No. 4 Single-Dose Accumultion Phrmcokinetics of Tobrmycin nd Netilmicin
More informationBody mass index, waist-to-hip ratio, and metabolic syndrome as predictors of middle-aged men's health
Originl Article - Sexul Dysfunction/Infertility pissn 2005-6737 eissn 2005-6745 Body mss index, wist-to-hip rtio, nd metbolic syndrome s predictors of middle-ged men's helth Jung Hyun Prk *, In-Chng Cho
More informationSandra Grbić Vladimir Lukić Ivan Kovačević Jelena Parojčić Zorica Đurić
Deprtment of Phrmceuticl Technology nd Cosmetology Fculty of Phrmcy University of Belgrde An investigtion into the possibilities nd limittions of in silico bsorption modeling: GstroPlus TM simultion of
More informationEffects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus
Originl Article Others Dibetes Metb J 215;39:335-341 http://dx.doi.org/1.493/dmj.215.39.4.335 pissn 2233-679 eissn 2233-687 DIABETES & METABOLISM JOURNAL Effects of 6-Month Sitgliptin Tretment on Insulin
More informationXII. HIV/AIDS. Knowledge about HIV Transmission and Misconceptions about HIV
XII. HIV/AIDS Knowledge bout HIV Trnsmission nd Misconceptions bout HIV One of the most importnt prerequisites for reducing the rte of HIV infection is ccurte knowledge of how HIV is trnsmitted nd strtegies
More informationLarry Alphs 1*, Cynthia A Bossie 1, Jennifer K Sliwa 1, Yi-Wen Ma 2 and Norris Turner 1. Abstract
PRIMARY RESEARCH Open Access Onset of efficcy with cute long-cting injectble pliperidone plmitte tretment in mrkedly to severely ill ptients with schizophreni: post hoc nlysis of rndomized, double-blind
More informationBIOSTATISTICS. Lecture 1 Data Presentation and Descriptive Statistics. dr. Petr Nazarov
Microrry Center BIOSTATISTICS Lecture 1 Dt Presenttion Descriptive Sttistics dr. Petr Nzrov 25-02-2011 petr.nzrov@crp-snte.lu Lecture 1. Dt presenttion descriptive sttistics COURSE OVERVIEW Orgniztion
More information2.3. with type 1 diabetes <3 years of age. (8.4)
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use HUMALOG sfely nd effectively. See full prescribing informtion for HUMALOG. HUMALOG (insulin lispro
More informationDiabetes affects 29 million Americans, imposing a substantial
CLINICAL Comprtive Effectiveness nd Costs of Insulin Pump Therpy for Dibetes Ronld T. Ackermnn, MD, MPH; Amish Wlli, MD, MS; Rymond Kng, MA; Andrew Cooper, MPH; Theodore A. Prospect, FSA, MAAA; Lewis G.
More informationR Martino 1, P Romero 1, M Subirá 1, M Bellido 1, A Altés 1, A Sureda 1, S Brunet 1, I Badell 2, J Cubells 2 and J Sierra 1
Bone Mrrow Trnsplnttion, (1999) 24, 283 287 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Comprison of the clssic Glucksberg criteri nd the IBMTR Severity
More informationENERGY CONTENT OF BARLEY
ENERGY CONTENT OF BARLEY VARIATION IN THE DIETARY ENERGY CONTENT OF BARLEY Shwn Firbirn, John Ptience, Hnk Clssen nd Ruurd Zijlstr SUMMARY Formultion of commercil pig diets requires n incresing degree
More informationAnalysis of alternatives for insulinizing patients to achieve glycemic control and avoid accompanying risks of hypoglycemia
284 Anlysis of lterntives for izing ptients to chieve glycemic control nd void ccompnying risks of hypoglycemi JIALIN GAO 1,2*, QIANYIN XIONG 1,2*, JUN MIAO 1*, YAO ZHANG 2,3, LIBING XIA 1, MEIQIN LU 1,
More informationDose-dependent effect of daptomycin on the artificial prolongation of prothrombin time in coagulation abnormalities: in vitro verification
Hshimoto et l. BMC Phrmcology nd Toxicology (2017) 18:74 DOI 10.1186/s40360-017-0180-3 RESEARCH ARTICLE Open Access Dose-dependent effect of dptomycin on the rtificil prolongtion of prothrombin time in
More informationAssessment of Depression in Multiple Sclerosis. Validity of Including Somatic Items on the Beck Depression Inventory II
Assessment of Depression in Multiple Sclerosis Vlidity of Including Somtic Items on the Beck Depression Inventory II Peggy Crwford, PhD; Noh J. Webster, MA Signs nd symptoms of multiple sclerosis (MS)
More informationTarget: 10 mg/day within several days Schizophrenia in adolescents (2.1)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ZYPREXA sfely nd effectively. See full prescribing informtion for ZYPREXA. ZYPREXA (olnzpine) Tblet
More informationBudesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
Journl of Crohn's nd Colitis, 2017, 785 791 doi:10.1093/ecco-jcc/jjx032 Advnce Access publiction Mrch 4, 2017 Originl Article Originl Article Budesonide Multimtrix Is Efficcious for Meslmine-refrctory,
More informationInvasive Pneumococcal Disease Quarterly Report. July September 2017
Invsive Pneumococcl Disese Qurterly Report July September 2017 Prepred s prt of Ministry of Helth contrct for scientific services by Rebekh Roos Helen Heffernn October 2017 Acknowledgements This report
More informationHypertension, hyperinsulinaemia and obesity in middle-aged Finns with impaired glucose tolerance
Journl of Humn Hypertension (1998) 12, 265 269 1998 Stockton Press. All rights reserved 0950-9240/98 $12.00 ORIGINAL ARTICLE Hypertension, hyperinsulinemi nd obesity in middle-ged Finns with impired glucose
More informationEffect of Oral Administration of Propylene Glycol on Serum Glucose Concentrations in Periparturient Dairy Cows
Ksetsrt J. (Nt. Sci.) 37 : 145-149 (2003) Effect of Orl Administrtion of Propylene Glycol on Serum Glucose Concentrtions in Periprturient Diry Cows Theer Rukkwmsuk, Nrongpol Petploi, Ing-orn Preechnvinit,
More informationAbstract. Background. Aim. Patients and Methods. Patients. Study Design
Impct of the Use of Drugs nd Substitution Tretments on the Antivirl Tretment of Chronic Heptitis C: Anlysis of Complince, Virologicl Response nd Qulity of Life (CHEOBS). Melin, 1 J.-. Lng, D. Ouzn, 3 M.
More informationIBUPROFEN DISPOSITION IN OBESE INDIVIDUALS
1117 BUPROFEN DSPOSTON N OBESE NDVDUALS DARRELL R. ABERNETHY nd DAVD J. GREENBLATT Eleven obese subjects (weight 114? 11 kg, men f SE) nd 11 ge-mtched subjects with norml body weight (61 f 3 kg) were given
More informationEVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1
Swine Dy 2001 Contents EVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1 C. W. Hstd, S. S. Dritz 2, J. L. Nelssen, M. D. Tokch, nd R. D. Goodbnd Summry Two trils were
More informationOriginal Article. T Akter 1, N Islam 2, MA Hoque 3, S Khanam 4, HA khan 5, BK Saha 6. Abstract:
Fridpur Med. Coll. J. 214;9(2):61-67 Originl Article Nebuliztion by Isotonic Mgnesium Sulphte Solution with Provide Erly nd Better Response s Compred to Conventionl Approch ( Plus Norml Sline) in Acute
More informationOlanzapine for the prophylaxis and rescue of chemotherapyinduced nausea and vomiting (CINV): a retrospective study
Originl Article Olnzpine for the prophylxis nd rescue of chemotherpyinduced nuse nd vomiting (CINV): retrospective study Leonrd Chiu, Nichols Chiu, Ronld Chow, Liying Zhng, Mrk Psetk, Jordn Stinson, Brenne
More informationImpact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting
Impct of Phrmcist Intervention on Dibetes Ptients in n Ambultory Setting Julie Stding, PhrmD, CDE, Jmie Herrmnn, PhrmD, Ryn Wlters, MS, Chris Destche, PhrmD, nd Aln Chock, PhrmD Dibetes is the seventh-leding
More informationShort-term therapy with lasting relief 2
# 1 PRESCRIBED MEDICATION APPROVED FOR IBS-D 1 * Short-term therpy with lsting relief 2 provided up to 6 months of symptom relief with 2-week tretment 2 Rnge of 6 to 24 weeks; medin of 10 weeks. Convenient
More informationAnemia in pediatric hemodialysis patients: Results from the 2001 ESRD Clinical Performance Measures Project
Kidney Interntionl, Vol. 64 (2003), pp. 1120 1124 Anemi in peditric hemodilysis ptients: Results from the 2001 ESRD Clinicl Performnce Mesures Project DIANE L. FRANKENFIELD, ALICA M. NEU, BRADLEY A. WARADY,
More informationEffectiveness of Belt Positioning Booster Seats: An Updated Assessment
ARTICLES Effectiveness of Belt Positioning Booster Sets: An Updted Assessment AUTHORS: Kristy B. Arbogst, PhD, Jessic S. Jermkin, DSc, Michel J. Klln, MS, b nd Dennis R. Durbin, MD, MSCE,b Center for Injury
More informationUNLOCKING SELF-POTENTIAL
ADVATE is FDA pproved for prophylxis in both dults & children (0-16 yers) 1 UNLOCKING SELF-POTENTIAL Setting Gols Worksheet Plese see pge 3 for ADVATE Indictions nd Detiled Importnt Risk Informtion. Plese
More informationPROVEN ANTICOCCIDIAL IN NEW FORMULATION
PROVEN ANTICOCCIDIAL IN NEW FORMULATION Coxidin 100 microgrnulte A coccidiosttic dditive for roilers, chickens rered for lying nd turkeys Contins 100 g of monensin sodium per kg Aville s homogenous grnules
More informationSleep Disordered Breathing and Gestational Hypertension: Postpartum Follow-up Study
SDB AND GESTATIONAL HYPERTENSION: POSTPARTUM FOLLOW-UP Sleep Disordered Brething nd Gesttionl Hypertension: Postprtum Follow-up Study John Reid, MD 1 ; Riley A. Glew, MPH 1 ; Robert Skomro, MD 1 ; Mrk
More informationSummary. Effect evaluation of the Rehabilitation of Drug-Addicted Offenders Act (SOV)
Summry Effect evlution of the Rehbilittion of Drug-Addicted Offenders Act (SOV) The Rehbilittion of Drug-Addicted Offenders Act (SOV) ws lunched on April first 2001. This lw permitted the compulsory plcement
More informationProduct Monograph INDICATIONS AND USAGE IMPORTANT RISK INFORMATION WARNING: RISK OF MEDICATION ERRORS AND HEPATOTOXICITY
Product Monogrph INDICATIONS AND USAGE OFIRMEV (cetminophen) injection is indicted for the mngement of mild to moderte pin, mngement of moderte to severe pin with djunctive opioid nlgesics, nd reduction
More informationINVEGA SUSTENNA (paliperidone palmitate) extended-release injectable
(pliperidone plmitte) extended-relese injectble suspension, for intrmusculr use HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively.
More informationEffect of Preoperative Intravenous Methocarbamol and Intravenous Acetaminophen on Opioid Use After Primary Total Hip and Knee Replacement
Feture Article Effect of Preopertive Intrvenous Methocrbmol nd Intrvenous Acetminophen on Opioid Use After Primry Totl Hip nd Knee Replcement THOMAS D. LOOKE, MD, PHD; CAMERON T. KLUTH, MBA bstrct Between
More informationSupplementary Online Content
Supplementry Online Content Zulmn DM, Pl Chee C, Ezeji-Okoye SC, et l. Effect of n intensive outptient progrm to ugment primry cre for high-need Veterns Affirs ptients: rndomized clinicl tril. JAMA Intern
More information58 % 50 % REDUCTION IN RISK OF OVERT HE RECURRENCE 1
FOR ADULT PATIENTS WITH OVERT HEPATIC ENCEPHALOPATHY (HE) significntly reduced the risk of overt HE recurrence nd HE-relted hospitliztions 1 58 % 50 % REDUCTION IN RISK OF OVERT HE RECURRENCE 1 REDUCTION
More informationPatient-Controlled Transdermal Fentanyl Versus Intravenous Morphine Pump After Spine Surgery
Ptient-Controlled Trnsderml Fentnyl Versus Intrvenous Morphine Pump After Spine Surgery Emily M. Lindley, PhD; Kenneth Millign, BS; Ryn Frmer, MD; Evlin L. Burger, MD; Viks V. Ptel, MD bstrct Ptient-controlled
More informationChronic high-sodium diet intake after weaning lead to neurogenic hypertension in adult Wistar rats
Chronic high-sodium diet intke fter wening led to neurogenic hypertension in dult Wistr rts 1 Pul Mglhães Gomes; 2 Rento Willin Mrtins Sá; 1 Giovn Lopes Aguir; 1 Milede Hnner Sriv Pes; 1 Andréi Crvlho
More informationEFFECT OF DIETARY ENZYME ON PERFORMANCE OF WEANLING PIGS
EFFECT OF DIETARY ENZYME ON PERFORMANCE OF WEANLING PIGS Finl report sumitted to Dniso Animl Nutrition E. vn Heugten nd B. Frederik North Crolin Stte University, Deprtment of Animl Siene Summry The urrent
More informationRecommended Dosage Regimen for AVYCAZ (ceftazidime and avibactam) b. AVYCAZ 1.25 grams (ceftazidime 1 gram and avibactam 0.25 grams) every 8 hours
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use AVYCAZ sfely nd effectively. See full prescribing informtion for AVYCAZ. AVYCAZ (ceftzidime nd vibctm)
More informationTHE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS
THE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS THE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS John F. Ptience nd Doug Gillis SUMMARY
More informationMeat and Food Safety. B.A. Crow, M.E. Dikeman, L.C. Hollis, R.A. Phebus, A.N. Ray, T.A. Houser, and J.P. Grobbel
Met nd Food Sfety Needle-Free Injection Enhncement of Beef Strip Loins with Phosphte nd Slt Hs Potentil to Improve Yield, Tenderness, nd Juiciness ut Hrm Texture nd Flvor B.A. Crow, M.E. Dikemn, L.C. Hollis,
More informationPharmacokinetics of Acyclovir Suspension in Infants and Children
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 1987, p. 1722-1726 0066-4804/87/111722-05$02.00/0 Copyright 1987, Americn Society for Microbiology Vol. 31, No. 11 Phrmcokinetics of Acyclovir Suspension in
More informationWork-related musculoskeletal disorders (WMSDs) among nursing personnel
Work-Relted Musculoskeletl Injuries nd Disorders Among Occuptionl nd Physicl Therpists Amy R. Drrgh, Wendy Huddleston, Phyllis King KEY WORDS ccidents, occuptionl moving nd lifting ptients musculoskeletl
More informationThese highlights do not include all the information needed to use ADVATE safely and effectively. See full prescribing information for ADVATE.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ADVATE sfely nd effectively. See full prescribing informtion for ADVATE. ADVATE [Antihemophilic Fctor
More informationMETHOD 4010 SCREENING FOR PENTACHLOROPHENOL BY IMMUNOASSAY
METHOD 4010 SCREENING FOR PENTACHLOROPHENOL BY IMMUNOASSAY 1.0 SCOPE AND APPLICATION 1.1 Method 4010 is procedure for screening solids such s soils, sludges, nd queous medi such s wste wter nd lechtes
More informationEFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE
Swine Dy 21 EFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE J. M. DeRouchey, M. D. Tokch, J. L. Nelssen, R. D. Goodbnd, S. S. Dritz 1, J. C. Woodworth, M. J. Webster, B. W.
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDAapproved patient labeling. Revised: 6/2016 FULL PRESCRIBING INFORMATION: CONTENTS*
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use BASAGLAR sfely nd effectively. See full prescribing informtion for BASAGLAR BASAGLAR (insulin glrgine
More informationFat intake in patients newly diagnosed with type 2 diabetes: a 4-year follow-up study in general practice
Originl ppers Ft intke in ptients newly dignosed with type 2 dibetes: 4-yer follow-up study in generl prctice Floris A vn de Lr, Eloy H vn de Lisdonk, Peter L B J Lucssen, J M H Tigchelr, Sski Meyboom,
More informationRates of weight change for black and white Americans over a twenty year period
Interntionl Journl of Obesity (2003) 27, 498 504 & 2003 Nture Publishing Group All rights reserved 0307-0565/03 $25.00 www.nture.com/ijo PAPER Rtes of weight chnge for blck nd white Americns over twenty
More informationEnhancing World Markets for Canadian Pulses through Secondary Processing and Value Added Research
Yer 3 Progress Report 2012-13 Enhncing World Mrkets for Cndin Pulses through Secondry Processing nd Vlue Added Reserch SPG Project # PRO1008 Progress Report: Yer 3 (August 1 st, 2012 July 31 st, 2013)
More informationRisks for All-Cause Mortality: Stratified by Age, Estimated Glomerular Filtration Rate and Albuminuria
Clinicl Prctice: Mini-Review Received: My 20, 2016 Accepted fter revision: December 14, 2016 Published online: Jnury 27, 2017 Risks for All-Cuse Mortlity: Strtified by Age, Estimted Glomerulr Filtrtion
More informationEffect on Glycemic, Blood Pressure, and Lipid Control according to Education Types
Originl Article http://dx.doi.org/10.4093/dmj.2011.35.6.580 pissn 2233-6079 eissn 2233-6087 D I A B E T E S & M E T A B O L I S M J O U R N A L Effect on Glycemic, Blood Pressure, nd Lipid Control ccording
More informationPNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :
PNEUMOVAX 23 is recommended y the CDC for ll your pproprite dult ptients t incresed risk for pneumococcl disese 1,2 : Adults ged
More informationOriginal Article INTRODUCTION. Korean Diabetes J 2010;34: doi: /kdj pissn eissn
Originl Article doi: 1.493/kdj.21.34.6.34 pissn 1976-918 eissn 293-265 The Smll Rice Bowl-Bsed Mel Pln ws Effective t Reducing Dietry Energy Intke, Body Weight, nd Blood Glucose Levels in Koren Women with
More information